低危急性心肌梗死患者经皮冠状动脉介入治疗后早期停用阿司匹林
这项多中心、开放标签、随机对照试验在40个欧洲中心纳入2246例急性心肌梗死患者,其中1942例在成功完全血运重建并完成1个月双联抗血小板治疗且无缺血或大出血事件后随机分为P2Y12抑制剂单药组(961例)和继续双联抗血小板治疗组(981例)。主要终点为随机化后11个月全因死亡、心肌梗死、支架血栓、卒中或大出血(BARC 3或5型)的复合终点,P2Y12抑制剂单药组发生率为2.1%,双联抗血小板治疗组为2.2%(差异-0.09个百分点,95%CI -1.39至1.20,非劣效性P=0.02)。BARC 2、3或5型出血在P2Y12抑制剂单药组为2.6%,双联抗血小板治疗组为5.6%(HR 0.46,95%CI 0.29至0.75,优效性P=0.002)。支架血栓发生率低且两组相似,严重不良事件发生率似乎相似。
要点
- 在成功完全血运重建并完成1个月双联抗血小板治疗无事件的低危急性心梗患者中,P2Y12抑制剂单药主要终点事件2.1% vs 继续双联抗血小板2.2%(差异-0.09个百分点,95%CI -1.39至1.20,非劣效性P=0.02)。
- P2Y12抑制剂单药组BARC 2、3或5型出血2.6% vs 继续双联抗血小板组5.6%(HR 0.46,95%CI 0.29至0.75,优效性P=0.002)。
- 支架血栓发生率低且两组相似,严重不良事件发生率似乎相似。
- 适用人群为急性心梗后7天内成功完全血运重建、已完成1个月双联抗血小板治疗且无缺血或大出血事件的患者。
适用人群与场景
- 成人急性心肌梗死患者,在心肌梗死后7天内成功完成完全血运重建,并已完成1个月双联抗血小板治疗且无缺血或大出血事件。
- 多中心、开放标签、随机试验,40个欧洲中心参与。
诊断标准与关键阈值
- 主要终点为随机化后11个月全因死亡、心肌梗死、支架血栓、卒中或大出血(BARC 3或5型)的复合终点,非劣效性界值为1.25个百分点。
- 主要次要终点为随机化后11个月BARC 2、3或5型出血(临床相关出血),检验优效性。
处置流程与药物剂量
- 符合条件的患者随机分配至转换为P2Y12抑制剂单药治疗,或继续双联抗血小板治疗额外11个月。
- P2Y12抑制剂具体药名、剂量、给药途径及频次原文未写明。
研究设计与关键结果
- 多中心、开放标签、随机对照试验,40个欧洲中心,2246例入组,1942例随机化:P2Y12抑制剂单药组961例,继续双联抗血小板治疗组981例。
- 主要终点事件:P2Y12抑制剂单药组20例(2.1%),双联抗血小板治疗组21例(2.2%),差异-0.09个百分点(95%CI -1.39至1.20),非劣效性P=0.02。
- BARC 2、3或5型出血:P2Y12抑制剂单药组2.6%,双联抗血小板治疗组5.6%(HR 0.46,95%CI 0.29至0.75,优效性P=0.002)。
- 支架血栓发生率低且两组相似;严重不良事件发生率似乎相似。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于急性心梗后7天内成功完全血运重建、已完成1个月双联抗血小板治疗且无缺血或大出血事件的患者,P2Y12抑制剂单药治疗在主要不良心脑血管事件上不劣于继续双联抗血小板治疗,且出血事件更少。
- 作者结论认为,在此类低危患者中,P2Y12抑制剂单药治疗不劣于继续双联抗血小板治疗,且出血发生率更低。
指南或共识出处
- TARGET-FIRST试验,ClinicalTrials.gov注册号NCT04753749,由MicroPort(法国)资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction that has been treated with guideline-recommended complete revascularization and a contemporary drug-eluting stent remains unclear.
METHODS: We conducted a multicenter, open-label, randomized trial at 40 European sites. Adults with acute myocardial infarction who had undergone successful complete revascularization within 7 days after the infarction and had subsequently completed 1 month of dual antiplatelet therapy with no ischemic or major bleeding events were randomly assigned to transition to a P2Y12 inhibitor as monotherapy or to continue dual antiplatelet therapy for an additional 11 months. The primary outcome was a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or major bleeding (defined by the Bleeding Academic Research Consortium [BARC] as a bleeding event of type 3 or 5) at 11 months after randomization (tested for noninferiority with a margin of 1.25 percentage points). The main secondary outcome was BARC type 2, 3, or 5 bleeding (clinically relevant bleeding) at 11 months after randomization (tested for superiority).
RESULTS: Among the 2246 enrolled patients, 1942 underwent randomization: 961 to receive P2Y12-inhibitor monotherapy and 981 to continue dual antiplatelet therapy. A primary-outcome event occurred in 20 patients (2.1%) in the P2Y12-inhibitor monotherapy group and in 21 patients (2.2%) in the dual antiplatelet therapy group (difference, -0.09 percentage points; 95% confidence interval [CI], -1.39 to 1.20; P = 0.02 for noninferiority). BARC type 2, 3, or 5 bleeding occurred in 2.6% of the patients in the P2Y12-inhibitor monotherapy group and in 5.6% of those in the dual antiplatelet therapy group (hazard ratio, 0.46; 95% CI, 0.29 to 0.75; P = 0.002 for superiority). Stent thrombosis was infrequent, and the incidence was similar in the two groups. The incidence of serious adverse events appeared to be similar in the two groups.
CONCLUSIONS: Among low-risk patients with acute myocardial infarction who had undergone early complete revascularization and had completed 1 month of dual antiplatelet therapy without complications, P2Y12-inhibitor monotherapy was noninferior to continued dual antiplatelet therapy with respect to the occurrence of adverse cardiovascular and cerebrovascular events and resulted in a lower incidence of bleeding events. (Funded by MicroPort [France]; TARGET-FIRST ClinicalTrials.gov number, NCT04753749.).
参考来源
- Tarantini G, Honton B, Paradies V, et al. Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. N Engl J Med. 2025. PMID: 40888726. doi:10.1056/NEJMoa2508808
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。